TENET HEALTHCARE CORP (THC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.61%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.61% | Share-based compensation / revenue. Period ending 2026-06-30. $132.00M ÷ $21.81B × 100 ≈ 0.61% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 21.81B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 132.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 4.54B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $21.81B | $132.00M | $4.54B | (m) | (m) | 0.61% | (m) | (m) |
| 2026-03-31 | (m) | $21.45B | $108.00M | $3.86B | (m) | (m) | 0.50% | (m) | (m) |
| 2025-12-31 | (m) | $21.31B | $104.00M | $3.51B | (m) | (m) | 0.49% | (m) | (m) |
| 2025-09-30 | (m) | $20.85B | $94.00M | $3.48B | (m) | (m) | 0.45% | (m) | (m) |
| 2025-06-30 | (m) | $20.68B | $72.00M | $3.68B | (m) | (m) | 0.35% | (m) | (m) |
| 2025-03-31 | (m) | $20.52B | $71.00M | $3.61B | (m) | (m) | 0.35% | (m) | (m) |
| 2024-12-31 | (m) | $20.66B | $67.00M | $5.96B | (m) | (m) | 0.32% | (m) | (m) |
| 2024-09-30 | (m) | $20.97B | $70.00M | $5.87B | (m) | (m) | 0.33% | (m) | (m) |
| 2024-06-30 | (m) | $20.92B | $69.00M | $5.35B | (m) | (m) | 0.33% | (m) | (m) |
| 2024-03-31 | (m) | $20.89B | $69.00M | $5.19B | $898.00M | (m) | 0.33% | 5.78× | Reported |
| 2023-12-31 | (m) | $20.55B | $66.00M | $2.51B | $901.00M | (m) | 0.32% | 2.79× | Reported |
| 2023-09-30 | (m) | $20.16B | $57.00M | $2.31B | $893.00M | (m) | 0.28% | 2.59× | Reported |
| 2023-06-30 | (m) | $19.89B | $55.00M | $2.34B | $888.00M | (m) | 0.28% | 2.63× | Reported |
| 2023-03-31 | (m) | $19.45B | $54.00M | $2.29B | $884.00M | (m) | 0.28% | 2.59× | Reported |
| 2022-12-31 | (m) | $19.17B | $56.00M | $2.33B | $890.00M | (m) | 0.29% | 2.62× | Reported |
| 2022-09-30 | (m) | $19.04B | $60.00M | $2.55B | $892.00M | (m) | 0.32% | 2.86× | Reported |
| 2022-06-30 | (m) | $19.13B | $60.00M | $2.97B | $897.00M | (m) | 0.31% | 3.31× | Reported |
| 2022-03-31 | (m) | $19.45B | $58.00M | $3.00B | $910.00M | (m) | 0.30% | 3.30× | Reported |
| 2021-12-31 | (m) | $19.48B | $56.00M | $2.87B | $923.00M | (m) | 0.29% | 3.11× | Reported |
| 2021-09-30 | (m) | $19.54B | $49.00M | $3.04B | $944.00M | (m) | 0.25% | 3.22× | Reported |
| 2021-06-30 | (m) | $19.21B | $47.00M | $2.30B | $980.00M | (m) | 0.24% | 2.34× | Reported |
| 2021-03-31 | (m) | $17.90B | $45.00M | $2.18B | $1.00B | (m) | 0.25% | 2.18× | Reported |
| 2020-12-31 | (m) | $17.64B | $44.00M | $1.99B | $1.00B | (m) | 0.25% | 1.98× | Reported |
| 2020-09-30 | (m) | $17.53B | $46.00M | $1.50B | $1.00B | (m) | 0.26% | 1.49× | Reported |
| 2020-06-30 | (m) | $17.54B | $46.00M | $1.53B | $985.00M | (m) | 0.26% | 1.55× | Reported |
| 2020-03-31 | (m) | $18.45B | $44.00M | $1.46B | $977.00M | (m) | 0.24% | 1.49× | Reported |
| 2019-12-31 | (m) | $18.48B | $42.00M | $1.51B | $985.00M | (m) | 0.23% | 1.54× | Reported |
| 2019-09-30 | (m) | $18.29B | $46.00M | $1.46B | $988.00M | (m) | 0.25% | 1.47× | Reported |
| 2019-06-30 | (m) | $18.21B | $49.00M | $1.48B | $993.00M | (m) | 0.27% | 1.49× | Reported |
| 2019-03-31 | (m) | $18.16B | $48.00M | $1.50B | $1.00B | (m) | 0.26% | 1.50× | Reported |
| 2018-12-31 | (m) | $18.31B | $46.00M | $1.65B | $1.00B | (m) | 0.25% | 1.64× | Reported |
| 2018-09-30 | (m) | (m) | $49.00M | $1.73B | $1.01B | (m) | (m) | 1.71× | Reported |
| 2018-06-30 | (m) | (m) | $50.00M | $1.46B | $1.02B | (m) | (m) | 1.43× | Reported |
| 2018-03-31 | (m) | (m) | $55.00M | $1.36B | $1.02B | (m) | (m) | 1.33× | Reported |
| 2017-12-31 | (m) | (m) | $59.00M | $1.11B | $1.03B | (m) | (m) | 1.08× | Reported |
| 2017-09-30 | (m) | (m) | $61.00M | $880.00M | $1.02B | (m) | (m) | 0.86× | Reported |
| 2017-06-30 | (m) | (m) | $62.00M | $1.17B | $1.01B | (m) | (m) | 1.16× | Reported |
| 2017-03-31 | (m) | (m) | $65.00M | $1.13B | $994.00M | (m) | (m) | 1.14× | Reported |
| 2016-12-31 | (m) | (m) | $68.00M | $1.22B | $979.00M | (m) | (m) | 1.25× | Reported |
| 2016-09-30 | (m) | (m) | $70.00M | $1.26B | $978.00M | (m) | (m) | 1.29× | Reported |
| 2016-06-30 | (m) | (m) | $71.00M | $1.22B | $983.00M | (m) | (m) | 1.24× | Reported |
| 2016-03-31 | (m) | (m) | $70.00M | $1.11B | $956.00M | (m) | (m) | 1.16× | Reported |
| 2015-12-31 | (m) | (m) | $69.00M | $1.06B | $912.00M | (m) | (m) | 1.16× | Reported |
| 2015-09-30 | (m) | (m) | $60.00M | $1.08B | $860.00M | (m) | (m) | 1.25× | Reported |
| 2015-06-30 | (m) | (m) | $58.00M | $1.00B | $798.00M | (m) | (m) | 1.26× | Reported |
| 2015-03-31 | (m) | (m) | $54.00M | $1.04B | $771.00M | (m) | (m) | 1.36× | Reported |
| 2014-12-31 | (m) | (m) | $51.00M | $925.00M | $754.00M | (m) | (m) | 1.23× | Reported |
| 2014-09-30 | (m) | (m) | $51.00M | $755.00M | $740.00M | (m) | (m) | 1.02× | Reported |
| 2014-06-30 | (m) | (m) | $43.00M | $692.00M | $645.00M | (m) | (m) | 1.07× | Reported |
| 2014-03-31 | (m) | (m) | $37.00M | $687.00M | $553.00M | (m) | (m) | 1.24× | Reported |
| 2013-12-31 | (m) | (m) | $36.00M | $663.00M | $474.00M | (m) | (m) | 1.40× | Reported |
| 2013-09-30 | (m) | (m) | $34.00M | $707.00M | $401.00M | (m) | (m) | 1.76× | Reported |
| 2013-06-30 | (m) | (m) | $34.00M | $712.00M | $413.00M | (m) | (m) | 1.72× | Reported |
| 2013-03-31 | (m) | (m) | $35.00M | $690.00M | $417.00M | (m) | (m) | 1.65× | Reported |
| 2012-12-31 | (m) | (m) | $32.00M | $749.00M | $412.00M | (m) | (m) | 1.82× | Reported |
| 2012-09-30 | (m) | (m) | $31.00M | $693.00M | $403.00M | (m) | (m) | 1.72× | Reported |
| 2012-06-30 | (m) | (m) | $29.00M | $616.00M | $359.00M | (m) | (m) | 1.72× | Reported |
| 2012-03-31 | (m) | (m) | $25.00M | $596.00M | $355.00M | (m) | (m) | 1.68× | Reported |
| 2011-12-31 | (m) | (m) | $24.00M | $650.00M | $375.00M | (m) | (m) | 1.73× | Reported |
| 2011-09-30 | (m) | (m) | $21.00M | $666.00M | $376.00M | (m) | (m) | 1.77× | Reported |
| 2011-06-30 | (m) | (m) | $21.00M | $684.00M | $424.00M | (m) | (m) | 1.61× | Reported |
| 2011-03-31 | (m) | (m) | $22.00M | $692.00M | $433.00M | (m) | (m) | 1.60× | Reported |
| 2010-12-31 | (m) | (m) | $22.00M | $634.00M | $424.00M | (m) | (m) | 1.50× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $23.00M | $538.00M | $445.00M | (m) | (m) | 1.21× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $33.00M | $311.00M | $418.00M | (m) | (m) | 0.74× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surgery Partners, Inc. (SGRY) | United States | $1.860B | -24.80 |
| Ardent Health, Inc. (ARDT) | United States | $1.478B | 17.91 |
| COMMUNITY HEALTH SYSTEMS INC (CYH) | United States | $0.405B | 1.87 |
| HCA Healthcare, Inc. (HCA) | United States | $93.934B | 15.49 |